There are 2846 resources available
Q&A
Presenter: All Speakers
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Slides
Webcast
Invited Discussant 1321MO, 1322MO and 1318MO
Presenter: Felipe Roitberg
Session: Mini Oral session: Policy and preventive strategies
Resources:
Slides
Webcast
460MO - Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Presenter: Komal Jhaveri
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 459MO and 460MO
Presenter: Myung-Ju Ahn
Session: Mini Oral session: Developmental therapeutics
Resources:
Slides
Webcast
Welcome and introductions
Presenter: Hanneke van Laarhoven
Session: Astellas Pharma Europe Ltd - Navigating the evolving landscape of locally advanced unresectable or metastatic G/GEJ adenocarcinoma
Resources:
Webcast
Personalizing Treatment in NSCLC: Recent Developments
Presenter: Enriqueta Felip
Session: Medscape Oncology Global - Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects
Resources:
Webcast
The current landscape for locally advanced unresectable or metastatic G/GEJ adenocarcinoma
Presenter: Hanneke van Laarhoven
Session: Astellas Pharma Europe Ltd - Navigating the evolving landscape of locally advanced unresectable or metastatic G/GEJ adenocarcinoma
Resources:
Webcast
Novel ADC Targets in NSCLC: Rationale and Diagnostic Considerations
Presenter: Michael Thomas
Session: Medscape Oncology Global - Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects
Resources:
Webcast
Emerging treatments for locally advanced unresectable or metastatic G/GEJ adenocarcinoma
Presenter: Eric Van Cutsem
Session: Astellas Pharma Europe Ltd - Navigating the evolving landscape of locally advanced unresectable or metastatic G/GEJ adenocarcinoma
Resources:
Webcast
Which Patients May Benefit From Emerging ADCs in NSCLC: Explaining the Clinical Trial Data
Presenter: Egbert Smit
Session: Medscape Oncology Global - Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects
Resources:
Webcast